Fig. 5: APO ameliorates IBD in the DSS-induced mouse colitis model. | Cell Death Discovery

Fig. 5: APO ameliorates IBD in the DSS-induced mouse colitis model.

From: Apomorphine is a novel necroptosis inhibitor targeting mixed lineage kinase domain-like protein oligomerization

Fig. 5: APO ameliorates IBD in the DSS-induced mouse colitis model.The alternative text for this image may have been generated using AI.

A Experimental design of DSS-induced colitis in mice. C57BL/6 mice were given a 2.5% DSS in the drinking water for 8 days. Re-APO or Ox-APO was administered intraperitoneally daily for 7 days starting on day 0. On day 8, the mice were sacrificed, and the colon tissues were collected. B Mouse colon tissues were collected, and the effect of Re-APO or Ox-APO on histopathology was evaluated by H&E and PAS staining. C Histological scores of each group were evaluated. Mean ± SD (n = 5). *p < 0.05, ***p < 0.001, one-way ANOVA. D DAI of colitis was measured as mean ± SD (n = 5). **p < 0.01, ***p < 0.001, t-test. E Colon length was measured. Representative images of the colon (left) and colon length (right). Mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA.

Back to article page